Loading organizations...
Pivotal bioVenture Partners China is a venture capital firm dedicated to strategic investments in the life sciences industry within the Greater China region. The firm provides capital and specialized expertise to innovative healthcare companies, fostering the development of novel therapeutics. It actively collaborates with portfolio businesses, addressing substantial unmet medical needs.
Operating under Nan Fung Life Sciences, a strategic initiative of the Nan Fung Group, Pivotal bioVenture Partners China was established to leverage the distinct opportunities of the Chinese healthcare market. The founding insight recognized growing domestic innovation and the critical demand for advanced medical solutions, prompting the creation of a dedicated regional investment platform.
The firm primarily supports emerging life science companies and entrepreneurs commercializing transformative healthcare solutions. Pivotal bioVenture Partners China aims to accelerate therapeutic development, improve patient outcomes, and enhance China's position as a significant contributor to global life sciences advancement.
Pivotal bioVenture Partners China has 4 tracked investments across 4 companies. The latest tracked deal is $13.5M Seed in Heranova Lifesciences in January 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 2, 2024 | Heranova Lifesciences | $13.5M Seed | — | Emerging Technology Partners, Sinovation Ventures |
| Nov 1, 2021 | Ablaze Pharmaceuticals | $75.0M Series A | Vivo Capital, Advantech Capital | Novo Ventures, VenBio Partners, NAN Fung Life Sciences, Rayz Investments, Samsara BioCapital, Venrock |
| Mar 1, 2021 | Arctic Vision | $100.0M Series B | ROY XIE | Cventures, Adrian Cheng, Morningside Ventures, NAN Fung Life Sciences, Octagon Capital, Tencent Holdings |
| Jan 1, 2021 | Visen Pharmaceuticals | $150.0M Series B | Hongshan Capital Group (Sequoia Capital China) | Qiming Venture Partners, Vivo Capital, Michael Wolff Jensen, CDG Capital, Cormorant Asset Management, HBM Healthcare Investments, Logos Capital, OrbiMed, Sherpa Healthcare Partners, Sofinnova Investments |
